AU2001262833A1 - Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect - Google Patents

Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Info

Publication number
AU2001262833A1
AU2001262833A1 AU2001262833A AU6283301A AU2001262833A1 AU 2001262833 A1 AU2001262833 A1 AU 2001262833A1 AU 2001262833 A AU2001262833 A AU 2001262833A AU 6283301 A AU6283301 A AU 6283301A AU 2001262833 A1 AU2001262833 A1 AU 2001262833A1
Authority
AU
Australia
Prior art keywords
patient
effect
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262833A
Other languages
English (en)
Inventor
Barrington Furr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001262833A1 publication Critical patent/AU2001262833A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001262833A 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect Abandoned AU2001262833A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012291.1A GB0012291D0 (en) 2000-05-23 2000-05-23 Pharmaceutical combination
GB0012291 2000-05-23
PCT/SE2001/001162 WO2001089515A1 (en) 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Publications (1)

Publication Number Publication Date
AU2001262833A1 true AU2001262833A1 (en) 2001-12-03

Family

ID=9892038

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262833A Abandoned AU2001262833A1 (en) 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Country Status (23)

Country Link
US (1) US20030134899A1 (pt)
EP (1) EP1292296A1 (pt)
JP (1) JP2003534278A (pt)
KR (1) KR20030001535A (pt)
CN (1) CN1431899A (pt)
AU (1) AU2001262833A1 (pt)
BR (1) BR0111051A (pt)
CA (1) CA2407028A1 (pt)
CZ (1) CZ20023785A3 (pt)
EE (1) EE200200654A (pt)
GB (1) GB0012291D0 (pt)
HK (1) HK1053061A1 (pt)
HU (1) HUP0302276A3 (pt)
IL (1) IL152545A0 (pt)
IS (1) IS6589A (pt)
MX (1) MXPA02011472A (pt)
NO (1) NO20025638L (pt)
NZ (1) NZ521979A (pt)
PL (1) PL363504A1 (pt)
RU (1) RU2002134483A (pt)
SK (1) SK16562002A3 (pt)
WO (1) WO2001089515A1 (pt)
ZA (1) ZA200208845B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1666033B1 (en) * 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2582195A1 (en) * 2005-03-29 2006-10-05 Usv Limited Process for preparation of bicalutamide
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (pt) * 1962-09-13
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX

Also Published As

Publication number Publication date
JP2003534278A (ja) 2003-11-18
NO20025638D0 (no) 2002-11-22
MXPA02011472A (es) 2004-09-06
NZ521979A (en) 2004-06-25
CA2407028A1 (en) 2001-11-29
US20030134899A1 (en) 2003-07-17
IS6589A (is) 2002-10-25
CZ20023785A3 (cs) 2003-03-12
NO20025638L (no) 2002-11-22
PL363504A1 (en) 2004-11-29
SK16562002A3 (sk) 2003-05-02
ZA200208845B (en) 2004-02-27
CN1431899A (zh) 2003-07-23
RU2002134483A (ru) 2004-06-27
IL152545A0 (en) 2003-05-29
HK1053061A1 (zh) 2003-10-10
GB0012291D0 (en) 2000-07-12
KR20030001535A (ko) 2003-01-06
HUP0302276A3 (en) 2005-06-28
BR0111051A (pt) 2003-04-15
WO2001089515A1 (en) 2001-11-29
EP1292296A1 (en) 2003-03-19
HUP0302276A2 (hu) 2003-11-28
EE200200654A (et) 2004-06-15

Similar Documents

Publication Publication Date Title
US5985868A (en) Methods and compositions for treating androgen-dependant diseases using optically pure R-(-) casodex
AU2004281708B2 (en) Treating bone-related disorders with selective androgen receptor modulators
TWI374737B (en) Treating benign prostate hyperplasia with sarms
US4201788A (en) Process for alleviating proliferative skin diseases
EA018699B1 (ru) Применение соединения селективного модулятора андрогеновых рецепторов
EP1289519B1 (en) Methods of treating androgen deficiency in men using clomiphene
US20030134899A1 (en) Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
US4207315A (en) Process for treating proliferative skin diseases using certain diamino compounds
KR20010029495A (ko) 전립선 비대 및 전립선 암을 치료하기 위한 수단
US20030158160A1 (en) Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
FR3082842A1 (fr) Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
JP2017522389A (ja) シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療
US20030114519A1 (en) Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
WO2001089516A1 (en) Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
WO2002002107A1 (en) Pharmaceutical combination of bicalutamide and letrozole for providing an anti-androgenic effect and aromatase inhibition
WO2002002112A1 (en) Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
WO2002002113A1 (en) Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
JP2023511612A (ja) 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物
US20050288230A1 (en) Non-steroidal anti-androgen therapy
TW200526201A (en) Treating bone-related disorders with selective androgen receptor modulators

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application